Introduction
B cell chronic lymphocytic leukemia (B-CLL) is the commonest leukemia in adults, representing around 0.8% of all cancers and nearly 30% of all leukemias. 1 The disease is characterized by the accumulation in blood of G 0 resting, long-lived, CD5
+ B cells that express high levels of the antiapoptotic protein Bcl-2. 1 Because of its indolent course, this leukemia is usually not treated in the early stages until progression occurs and then classically is treated with chlorambucil, an alkylating agent. Although this is still a standard protocol, the use of nucleoside analogues as front-line therapy is rapidly increasing. The main nucleoside analogues currently used for B-CLL treatment are fludarabine (9-␤-D-arabinofuranosyl-2-fluoroadenine, F-ara-A) and cladribine (2-chloro-2Ј-deoxyadenosine, 2CdA). 1 Cladribine is resistant to deamination by adenosine deaminase, a key enzyme in purine catabolism, causing its accumulation in cells. Selectivity for lymphocytes is due to the high level of deoxycytidine kinase and low level of 5Ј-nucleotidase activities in lymphocytes, compared with other body cells, thus favoring the accumulation of 2CdATP, the active form of drug.
2 F-ara-A and 2CdA induce apoptosis in B-CLL cells, but the molecular pathways involved in cell death are not well known. In particular, the relative role of caspases and apoptosis-inducing factor (AIF) is not well defined. Most works have investigated the apoptotic mechanism triggered by F-ara-A and the information concerning 2CdA is more limited. Treatment of sensitive B-CLL cells with F-ara-A induces caspase-3 activation in vitro 3, 4 and treatment with the pan-caspase inhibitor Z-VAD-fmk prevented caspase-3 activity but not cell death. 3, 5 It is not known whether other caspases are also activated. In a previous work on the mechanism of 2CdA-induced apoptosis in B-CLL cells, 6 the induction of caspase activity upon 2CdA-treatment was established but the precise identity of activated caspases and the necessity of caspases for cell death was not established.
We have recently studied the mechanism of 2CdA-induced apoptosis in several cell lines representative of the main human leukemic lineages 7 and have found a differential implication of caspases in the induction phase of apoptosis depending on cell types. In the present work, we have studied the role of caspases and apoptosis-inducing factor (AIF) in apoptosis induced by 2CdA, in vitro, in cells from patients with B-CLL and in peripheral blood lymphocytes from normal donors. Results indicate that 2CdA causes ⌬⌿ m loss and subsequent activation of caspases involved in the mitochondrial route of apoptosis. 2CdA also induces translocation of AIF from mitochondria to nucleus. Inhibition of caspase activity prevented the development of classical apoptotic phenotype but not ⌬⌿ m loss, AIF translocation and cell death.
Materials and methods

Cell isolation and culture
Peripheral blood was obtained from 22 patients (13 men and 9 women), all with classic B-CLL, who had not been previously treated or remained untreated for the previous 6 months, with a median age of 66 years (range, 50-75 years), as well as normal donors. B-CLL was diagnosed according to standard laboratory and clinical criteria and patients represented a spectrum of clinical stages. The median white cell count was of 65 ϫ 10 9 leukocytes/l (range 12 to 400 × 10 9 leukocytes/l) and B-CLL cells were CD5
− , weak surface Ig and Ͻ5% prolymphocytes. Mononuclear cells (PBMC) from blood samples of B-CLL patients, prior to treatment, or normal donors were isolated from blood samples by Ficoll-Paque density centrifugation, as described. 8 B-CLL cells were resuspended at 5 × 10 6 cell/ml and immediately cultured in RPMI 1640 medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 g/ml streptomycin (hereafter, complete medium). Cells from most patients were also cryopreserved in liquid nitrogen, in the presence of 10% DMSO, and used, when necessary, for further analysis. Preliminary experiments revealed that in vitro sensitivity of fresh or frozen cells to drugs was essentially the same, as previously described by other authors. 4, 5 T cell blasts were generated from isolated normal PBMC as follows: PBMC (2 × 10 6 cells/ml) were treated with 2 g/ml PHA (Sigma, Madrid, Spain) for 16 h in complete medium. Then, PHA was washed out and cells resuspended in complete medium supplemented with 30 U/ml IL-2 (Life Technologies, Barcelona, Spain). Cells were cultured for 6-8 days with medium changes every 2 days prior to cytotoxicity testing.
Evaluation of cell toxicity
Cells (2 × 10 6 cells/ml for normal PBMC and T cell blasts or 5 × 10 6 cells/ml for B-CLL cells) were treated in 24-well plates (1 ml/well) with 1 M 2CdA (cladribine, kindly provided by Janssen-Cilag, Madrid, Spain) or 10 M F-ara-A (fludarabine phosphate, Schering, Berlin, Germany) in complete medium for 2-4 days, as indicated. For apoptosis inhibition assays, cells were preincubated for 1 h with either 100 M Z-VADfmk (Bachem, Switzerland) or 0.5 g/ml cycloheximide prior to the addition of 2CdA or F-ara-A. When indicated, cells were supplemented with IL-2 (30 U/ml) and/or IL-4 (20 ng/ml) during assays. At different times of incubation with drugs, cell viability was determined by morphological inspection of Trypan blue-stained cells. 9 Apoptosis was assayed by flow cytometry by determining changes in forward/side scatter, phosphatidylserine (PS) exposure and loss of mitochondrial membrane potential (⌬⌿ m ). PS exposure during apoptosis was evaluated by annexin V binding. Briefly, cells (5 × 10 5 in 200 l) were incubated with 0.5 g/ml annexin V-PE (Caltag, Barcelona, Spain) in binding buffer (140 mM NaCl, 2.5 mM CaCl 2 , 10 mM Hepes/NaOH, pH 7.4), at room temperature for 30 min. Then, cells were diluted with 1 ml binding buffer and analyzed. For determination of mitochondrial membrane potential (⌬⌿ m ), cells (5 × 10 5 in 200 l) were incubated with 20 nM DiOC 6 (3) (Molecular Probes, Leiden, The Netherlands) in complete medium for 20 min at 37°C. Cells were diluted with PBS to a final volume of 1 ml and analyzed by flow cytometry. 9 In some samples, dual labelling with annexin V-PE and DiOC 6 (3) was performed. In these cases, the annexinlabelling protocol was used. Chromatin condensation and nuclear fragmentation during apoptosis were analyzed by pphenylenediamine (PPDA) staining and fluorescence microscopy as described previously. 10 
Immunofluorescence staining
Cells (5 × 10 6 in 1 ml) were seeded in complete medium with or without 1 M 2CdA and cultured for 48 h. At the end of incubation, cells were washed once in PBS and fixed with 4% paraformaldehyde for 15 min. Then, cells were centrifuged on to poly-L-lysine coated glass coverslips. Coverslips were then washed once in PBS and briefly immersed in 0.1% saponin in PBS. Coverslips were then placed on to a drop of a 1/150 dilution of goat anti-AIF antiserum in PBS containing 0.1% saponin and 10% normal goat serum and incubated at room temperature in a humidified chamber for 30 min. Coverslips were then washed twice with a saponin solution and incubated in the same way with a 1/200 dilution of a FITC-labelled Leukemia anti-rabbit IgG antibody (Caltag). Finally, coverslips were sequentially washed with 0.1% saponin, PBS and distilled water, mounted on to glass slides over a drop of Mowiol (Calbiochem, Madrid, Spain) and stored at 4°C in the dark until observation. Preparations were analyzed in a Zeiss (Madrid, Spain) 310 confocal microscope.
Analysis of caspase activation and levels of apoptosisregulatory proteins
Caspase activation and levels of Bcl-2 superfamily proteins were analyzed by Western blot. Cells were lysed in 50 mM Tris/HCl pH 7.6 buffer containing 0.15 M NaCl, 1 mM EDTA, 10 g/ml leupeptin, 1 mM PMSF and 1% Triton X-100. Solubilized proteins from equal numbers of extracted cells (4 × 10 6 Trypan blue-negative cells for each lane) were resolved by SDS-12% PAGE, transferred to nitrocellulose membranes (Hybond-C extra, Amersham, Barcelona, Spain) and incubated with primary antibodies diluted in TBS-T (10 mM Tris/HCl pH 8, 0.12 M NaCl, 0.1% Tween-20, 0.05% sodium azide), containing 5% skimmed milk, as described previously. 10 Primary antibodies used were: mouse monoclonal anti-caspase-3 (0.25 g/ml, clone 19, BD Transduction Laboratories, Madrid, Spain); monoclonal anti-caspase-7 (1 g/ml, clone B94-1, BD Pharmingen, Madrid, Spain); monoclonal anti-caspase-8 (1 g/ml, UBI, clone 5F7) rabbit antiserum anti-human caspase-9 (1/6000, cat. No. 68086E, BDPharmingen), rabbit anti-human Bax (1/500, cat. No. 554104, BD Pharmingen); rabbit anti-human Bak (1/500, cat. No. 06-536, UBI), rabbit polyclonals anti-Bcl-2 (1/500, sc-783), anti-Mcl-1 (1/500, sc-819) and anti-Bik (1/500, sc-1710), all from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Membranes were washed with TBS-T and incubated with 0.2 g/ml of the corresponding phosphatase alkaline-labelled secondary antibody (Sigma). Western blots were revealed with the BCIP/NBT substrate, as described. Control of protein loading was achieved by reprobing with anti-␤ actin (1/10 000) or anti-␣ tubulin (1/2000) antibodies, both from Sigma. Rabbit polyclonal anti-AIF antibody was kindly provided by Drs Santos Susin and Guido Kroemer (CNRS, Villejuif, France). Western blots were analyzed for several proteins by a modification of the multiple blotting assay method. 11 In brief, after revealing the blot for one determined protein, the membrane was digitalized by computerized scanning. Then, the blot was sequentially reincubated with the appropriate dilution of a new primary antibody, its corresponding secondary antibody, revealed again with BCIP/NBT and further scanned. This technique allows analysis of up to four different protein bands in the same blot lane, provided that the antibodies are specific.
Results
Characteristics of 2CdA-induced apoptosis in B-CLL cells
The data on the in vitro sensitivity to 2CdA of B-CLL cells from the 22 patients are summarized in Table 1 . Apoptosis was quantified by determining PS exposure and loss of ⌬⌿ m . In all cases, both parameters were comparable, although the amount of cells displaying a low ⌬⌿ m was always slightly greater than those with exposed PS. For the purpose of this study, B-CLL cells were designated as 'sensitive' if after treatment with 1 M 2CdA for 72 h the percentage of ⌬⌿ low m cells at 72 h). In general, in cells showing a partial response, toxicity was significant after 48 h incubation but it only increased slightly thereafter. As previously found, 7, 12 apoptosis induced by 2CdA was not dependent on de novo protein synthesis, since treatment with cycloheximide did not prevent 2CdA toxicity (data not shown). Co-treatment of B-CLL cells with the pan-caspase inhibitor Z-VAD-fmk prevented the development of classical apoptotic morphology (Figure 1a ) but did not block 2CdA-induced death. In cells treated with 2CdA and Z-VAD-fmk, nuclei displayed only peripheral chromatin condensation (Figure 1a) , characteristics of AIF action 13 (see later). Flow cytometry analysis revealed that Z-VAD-fmk attenuated 2CdA-induced cell shrinking, as determined by forward/side scatter measurements (not shown). Treatment with Z-VADfmk reduced significantly the amount of annexin V-positive cells at 48 h, but not at 72 h (Figure 1b) . In most patients, this inhibition of PS translocation was moderate (eg patient Nos 1 and 13), although in a few patients, such as patient No. 10, Z-VAD-fmk greatly delayed PS translocation at 48 but not at 72 (Figure 1b) . Co-treatment with Z-VAD-fmk retarded ⌬⌿ m loss and so a significant proportion of cells displayed an intermediate ⌬⌿ m both at 48 h and 72 h (Figure 1b) . Cells from patients sensitive to 2CdA were also sensitive to F-ara-A in a comparable extent (Figure 2) . However, the degree of toxicity elicited by 1 M 2CdA at a given time-point was always slightly greater than that of 10 M F-ara-A 24 h later ( Figure  2) . Cells from one of the three patients resistant to 2CdA in vitro were tested for F-ara-A sensitivity and found also to be Leukemia resistant (Figure 2) . A high rate of spontaneous cell death was observed in cultured B-CLL cells from some patients (Table  1) , making it difficult to ascertain the degree of specific response to 2CdA. Addition of IL-4 to media greatly reduced spontaneous cell death of cultured B-CLL cells from all patients tested (Figure 3 ). In patients with a high rate of spontaneous cell death such as patients 4 and 22, but sensitive to 2CdA and F-ara-A, IL-4 only marginally reduced the toxicity elicited by both drugs. However, in patients with a moderate spontaneous cell death, such as patients 18 and 8 and showing a partial response to 2CdA and F-ara-A, IL-4 reduced the degree of apoptosis induced by 2CdA or F-ara-A (Figure 3 and data not shown).
All patients included in this study received treatment with 2CdA in vivo. Response to treatment was evaluated according to established clinical criteria 14 and is in Table 1 . Four of the 22 patients included in this study prematurely abandoned the treatment. Two patients died from other pathologies and in two others treatment with 2CdA was interrupted because of toxicity. In general, a good correlation between the in vitro and in vivo response was obtained in the remaining 18 patients receiving treatment with 2CdA.
Caspase activation in response to 2CdA
Caspases 3, 7, 8 and 9 were activated in cells from sensitive patients, as determined by the decrease in the intensity of the proenzyme in Western blots (Figure 4a) . Conversely, no significant activation of these caspases was observed in poorly responding cells. Lack of expression of some caspases was observed in cells from six patients ( Table 2) . Cells from patients 6, 7, 8 and 19 showed very low or no caspase 3 expression and those from patients 17 and 18 lacked caspase 9. In four of six of these patients, lack of expression of caspases 3 and 9 was associated with a partial or no response to 2CdA in vitro and in vivo. However, cells from patient No. 11 which were resistant to 2CdA both in vitro and in vivo (Table 1 ) expressed all the caspases analyzed, although they were not activated by 2CdA treatment (Figure 4a ). Although the small number of patients does not allow definitive conclusions to be established, there seems to be a trend to a worse clinical response in B-CLL patients lacking caspase 9.
Expression of Bcl-2 superfamily proteins
We also determined the expression of some pro-and antiapoptotic proteins of the Bcl-2 superfamily in the B-CLL cells studied. B-CLL cells from most patients expressed high levels of Bcl-2, Bax and Bak proteins and no significant variations in their levels were noticed upon treatment (Figure 4b ). Mcl-1 levels decreased in cells sensitive to 2CdA (Figure 4b ), according to previous reports 4, 15 but not in resistant cells. Bik was only expressed at low levels by cells of some patients. Bcl-X L and Bad were not detected.
Leukemia
Effect of 2CdA treatment on cellular AIF distribution
B-CLL cells of all patients studied expressed AIF protein, which appeared in Western blots as a doublet with a major band of around 67 kDa and a minor band of 65 kDa ( Figure  5 ). This microheterogeneity is probably due to interaction of AIF with the gel matrix. 16 Immunofluorescence analysis revealed that AIF protein showed a punctuate cytoplasmic pattern with some preferential localization in the perinuclear area in untreated B-CLL cells ( Figure 5 ). Upon 2CdA treatment, labelling in sensitive cells became diffuse and the intranuclear presence of AIF could be seen by confocal microscopy ( Figure 5 ). AIF translocation from cytoplasm to nucleus was not significantly inhibited by cotreatment with the general caspase inhibitor Z-VAD-fmk ( Figure 5 ) or with Ac-DEVD-CHO, a selective inhibitor of caspases 3, 7 and 8 (data not shown). In B-CLL cells resistant to 2CdA the percentage of cells showing nuclear AIF labelling was very low and similar in cells cultured in the presence or absence of drug (not shown).
Effect of Z-VAD on 2CdA toxicity on normal lymphocytes
Since 2CdA-induced apoptosis of B-CLL cells was not prevented by the pan-caspase inhibitor Z-VAD-fmk, we investigated whether this peptide could spare normal blood T cells from B-CLL patients from 2CdA-induced apoptosis. We first evaluated the toxicity of 2CdA on normal PBMC. 2CdA and F-ara-A induced apoptosis in normal resting T lymphocytes, as previously reported, 2,4 as well as in T cell blasts (Figure 6a ). Cell death was not prevented either by cotreatment with Z-VAD-fmk (Figure 6b ) or with the selective inhibitor Ac-DEVD-CHO (not shown). Supplementation with IL-2, IL-4 or both did not prevent 2CdA toxicity either in the presence or absence of Z-VAD-fmk ( Figure 6 ). Moreover, flow cytometry analysis revealed that CD3 + and CD19 + peripheral blood cells from B-CLL patients were similarly killed by 2CdA in the presence of Z-VAD-fmk (not shown).
Discussion
B-CLL is a leukemia characterized for the accumulation in blood of long-lived, abnormally differentiated CD5 + B cells. The main molecular defect underlying this neoplasia is impaired apoptosis rather than excessive proliferation. 17 However, in spite of their natural resistance to apoptosis, B-CLL cells are usually sensitive to a variety of chemotherapeutic drugs. These include alkylating agents (chlorambucil), 18 topoisomerase inhibitors (mitoxantrone), 19 anthracyclines (doxorubicin) 20 and nucleoside analogues (fludarabine and cladribine). 1 Although nucleoside analogues were first used as secondary drugs, their use as a front-line treatment is becoming habitual because of their better overall response rate. 1, 21 It was soon realised that F-ara-A and 2CdA treatment induced DNA fragmentation, a hallmark of apoptosis, in both normal and tumoral lymphocytes. 22 However, the current knowledge on the molecular mechanism of apoptosis induced by F-ara-A and 2CdA is still partial. This is of interest since the pharmacological resistance to these drugs could be due in part to a failure in the apoptotic machinery. 17 It is commonly accepted that chemotherapeutic drugs induce apoptosis through the denominated mitochondrial pathway. 23 After reaching their intracellular targets, the drug causes a cell malfunction that leads to the generation of a death signal. This signal arrives to mitochondria causing loss of ⌬⌿ m and the release of cytochrome c and AIF to cytoplasm. Cytochrome c binds to the adaptor Apaf-1 and the complex recruits and activates caspase 9, which initiates a caspase cascade, responsible for the hydrolysis of key cytoplasmic proteins. 24 On the other hand, AIF migrates to the nucleus and induces high molecular weight DNA fragmentation and marginal chromatin condensation. 13 The combined action of caspases and AIF produce the typical apoptotic phenotype (cell shrinking, blebbing, nuclear condensation and fragmentation). In most cases, loss of ⌬⌿ m marks the point of no return between the induction and the execution phase of apoptosis. 25 While the involvement of caspases in the execution of drug-induced apoptosis is firmly documented, their participation in the induction phase is variable. In specific leukemic cells exposed to certain drugs, caspases are involved in the onset of cell death since cotreatment with Z-VAD-fmk blocks the development of apoptotic phenotype and cell death. 9, 26, 27 However, in other cell types or with other drugs, caspases seem only to be involved in execution of apoptosis and Z-VAD-fmk does not prevent death. 7, 23, 28 Our present results indicate that 2CdA treatment of sensitive B-CLL cells induces activation of at least caspases 3, 7, 8 and 9 (Figure 4a , patient No. 4). Inhibition of all caspase activity with Z-VAD-fmk prevented the development of the typical apoptotic morphology but did not avoid cell death. A similar effect of Z-VAD-fmk has been found in B-CLL cells treated with F-ara-A 5 and in the U937 promonocytic leukemia treated with 2CdA. 7 Our present results also show that caspase inhibition does not block the nuclear translocation of AIF induced by 2CdA or F-ara-A. These cells display a peripheral chromatin condensation, characteristic of the AIF action, which is due to the hydrolysis of DNA into high molecular weight (HMW) fragments. 13 This role of AIF in apoptosis agrees with the reported generation of HMW DNA fragments in B-CLL cells treated with F-ara-A. 29 In accordance with the dispensable role of caspases in cell death, very low or negligible levels of caspase 3 in cells from two patients did not prevent 2CdA-(or F-ara-A)-induced apoptosis. Lack or reduced caspase 3 expression has been previously found in cells from some B-CLL patients and this was not associated with F-ara-A resistance. 15 However, B-CLL cells from two patients that were defective in caspase 9 expression responded poorly to 2CdA, both in vitro and in vivo. Although this small number of patients does not allow definitive conclusions to be established, these results suggest that lack of caspase 9 expression might be associated with a poor response to nucleoside analogues in B-CLL. However, it is worth noting that lack of caspase 9 is probably not the main reason for 2CdA resistance. Patient No. 17 also expressed a very low level of caspase 8 and lacked p53 protein (unpublished results). Thus, it is possible that resistance to apoptosis induced by nucleoside analogues could be caused by the accumulation of several deficiencies in proteins involved in apoptotic pathways.
On the other hand, while execution of apoptosis caused by 2CdA or F-ara-A is performed by active caspases and AIF action, the molecules responsible for the induction of apoptosis remain to be unequivocally identified. It was reported that 2CdA and F-ara-A can bind to and activate Apaf-1 leading to caspase 9 activation and apoptosis. However, the activation potency of F-ara-A was much greater than that of 2CdA, contrary to the relative toxicity observed in cells. 30, 31 Anyway, since toxicity of both drugs is not prevented by casLeukemia pase inhibitors, a non-caspase factor must be a key inducer of cell death. A direct interaction of 2CdATP with mitochondria, leading to ⌬⌿ m loss, has been proposed 6 but the very high concentration of 2CdATP needed (500 M) casts doubt on the relevance of this process in vivo.
Experiments using lymphoid proliferating cells showed that F-ara-A, but not 2CdA, required previous incorporation into DNA for cytoxicity. 7, 32, 33 However, this process does not seem to be the main trigger of apoptosis since 2CdA and F-ara-A kill similarly resting and proliferating lymphocytes (this work and Ref. 2). It has been recently suggested that F-ara-A may cause cytotoxicity through inhibition of RNA transcription. 34 In any case, after affecting to DNA or RNA syntesis, the cell must generate signals, still undefined, that induce the apoptosis mechanism. Our results are compatible with the hypothesis that commitment to death in response to 2CdA and F-ara-A in B-CLL cells could be mediated by a still unidentified non-caspase factor. One or several proapoptotic members of the Bcl-2 superfamily are attractive candidates for such a factor. We have found that 2CdA induces a decrease in levels of the antiapoptotic protein Mcl-1 in a B cell line (JM1) 7 and in B-CLL cells (this work), as does F-ara-A in B-CLL cells, 4, 15 supporting the implication of Mcl-1 in apoptosis of B cells. B-CLL cells expressed significant amounts of Bax and Bcl-2 proteins, which did not significantly change with 2CdA treatment, according to Ref. 35 and it as previously found with Fara-A by most 4, 15, 36, 37 but not all 38 authors. However, Bcl-2 overexpression prevented 2CdA-induced apoptosis in CEM 6 and Jurkat cells. 7 A possible role of Bid can be ruled out since Bid requires its previous proteolytic activation by caspase 8 39 and caspase inhibition does not prevent cell death.
In conclusion, caspases and AIF independently mediate the execution phase of 2CdA-induced apoptosis in B-CLL cells. Under conditions of caspase inhibition, cell death is executed by AIF. A non-caspase factor, acting on mitochondria, is responsible for the commitment to cell death after drug treatment. The identification of that factor will be central in elucidating the mechanism of 2CdA-and F-ara-A-induced apoptosis and evaluating if defects in apoptotic machinery could explain in part the clinical resistance to these drugs.
